TY - JOUR
T1 - Human esophageal carcinomas frequently express the tumor‐rejection antigens of MAGE genes
AU - Inoue, Hiroshi
AU - Mori, Masaki
AU - Li, Jian
AU - Mimori, Koshi
AU - Honda, Masayuki
AU - Nakashima, Hideaki
AU - Mafune, Ken‐Ichi ‐I
AU - Tanaka, Youichi
AU - Akiyoshi, Tsuyoshi
PY - 1995/11/15
Y1 - 1995/11/15
N2 - Thde human genes MAGE‐1 and ‐3 encode melanoma peptide antigens that are recognized bhd autologous cytotoxic T lymphocytes. Tumors expressing MAGE genes are potential targets for cancer immunotherapy, because MAGE genes are expressed only in tumor tissue and not in any normal tissue except testis and placenta. However, little is known about MAGE gene expression in human esophageal carcinoma. The purpose of this study was therefore to analyze MAGE gene status in human esophageal carcinoma. We studied the expression status of these genes in 42 surgical samples and in 12 cell lines of human esophageal carcinoma using the reverse transcription polymerase chain reaction (RT‐PCR). Various clinicopathological factors were also analyzed. No MAGE gene expression was seen in any of the 42 normal esophageal tissue specimens. In contrast, tumor tissue expressed MAGE‐1, ‐2, and ‐3 in 26, 18 and 24 specimens, respectively. Thirty‐three of 42 tumors expressed at least one MAGE gene. Significant clinicopathologic differences between the tumors were not observed, regardless of the presence or absence of MAGE gene expression. In cell lines, MAGE‐1, ‐2, and ‐3 gene expression was recognized in 5, 4 and 4 cell lines, respectively. This study demonstrates that MAGE genes are frequently expressed in clinical samples as well as in cell lines of esophageal carcinoma. The identification of MAGE genes, therefore, may open up a new modality of treatment, namely specific immunotherapy, for patients with esophageal carcinoma.
AB - Thde human genes MAGE‐1 and ‐3 encode melanoma peptide antigens that are recognized bhd autologous cytotoxic T lymphocytes. Tumors expressing MAGE genes are potential targets for cancer immunotherapy, because MAGE genes are expressed only in tumor tissue and not in any normal tissue except testis and placenta. However, little is known about MAGE gene expression in human esophageal carcinoma. The purpose of this study was therefore to analyze MAGE gene status in human esophageal carcinoma. We studied the expression status of these genes in 42 surgical samples and in 12 cell lines of human esophageal carcinoma using the reverse transcription polymerase chain reaction (RT‐PCR). Various clinicopathological factors were also analyzed. No MAGE gene expression was seen in any of the 42 normal esophageal tissue specimens. In contrast, tumor tissue expressed MAGE‐1, ‐2, and ‐3 in 26, 18 and 24 specimens, respectively. Thirty‐three of 42 tumors expressed at least one MAGE gene. Significant clinicopathologic differences between the tumors were not observed, regardless of the presence or absence of MAGE gene expression. In cell lines, MAGE‐1, ‐2, and ‐3 gene expression was recognized in 5, 4 and 4 cell lines, respectively. This study demonstrates that MAGE genes are frequently expressed in clinical samples as well as in cell lines of esophageal carcinoma. The identification of MAGE genes, therefore, may open up a new modality of treatment, namely specific immunotherapy, for patients with esophageal carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0028892953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028892953&partnerID=8YFLogxK
U2 - 10.1002/ijc.2910630411
DO - 10.1002/ijc.2910630411
M3 - Article
C2 - 7591261
AN - SCOPUS:0028892953
VL - 63
SP - 523
EP - 526
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 4
ER -